Compare Proprius Pharmaceuticals vs Relypsa
Customers evaluate the quality of Proprius Pharmaceuticals's products using the following success metrics.
Overview
Proprius Pharmaceuticals is based in United States
Cypress Bioscience, Inc. (NASDAQ: CYPB) and Proprius Pharmaceuticals, Inc., a privately held, San Diego-based specialty pharmaceutical company, today announced that Cypress will acquire Proprius in a transaction that includes an upfront payment of $37.5 million in cash as well as an additional $37.5 million in potential milestone-related payments associated with the development of Proprius' therapeutic candidates.
Relypsa is based in United States
Relypsa is a clinical-stage biopharmaceutical company leading the discovery and development of non-absorbed polymeric drugs for applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the treatment of hyperkalemia. Relypsa is pursuing the discovery of additional product candidates through use of its polymer platform.
Demo Video
Leadership
Michael J Walsh (Chief Executive Officer, President)
Jerry M Buysse (Chief Security Officer)
Investors
Cypress Bioscience, Atlas Venture
Galenica , Delphi Ventures
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Proprius Pharmaceuticals has not claimed their profile.
Work for Proprius Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Proprius Pharmaceuticals?
Claim your profile now.
Information not available because Relypsa has not claimed their profile.
Work for Relypsa? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Relypsa?
Claim your profile now.